Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Julian Ip is active.

Publication


Featured researches published by Julian Ip.


PLOS ONE | 2012

Comprehensive Re-Sequencing of Adrenal Aldosterone Producing Lesions Reveal Three Somatic Mutations near the KCNJ5 Potassium Channel Selectivity Filter

Tobias Åkerström; Joakim Crona; Alberto Delgado Verdugo; Lee F. Starker; Kenko Cupisti; Holger S. Willenberg; Wolfram T. Knoefel; Wolfgang Saeger; Alfred Feller; Julian Ip; Patsy S. Soon; Martin Anlauf; Pier Francesco Alesina; Kurt Werner Schmid; Myriam Decaussin; Pierre Levillain; Bo Wängberg; Jean-Louis Peix; Bruce G. Robinson; Jan Zedenius; Stefano Caramuta; K. Alexander Iwen; Johan Botling; Peter Stålberg; Jean-Louis Kraimps; Henning Dralle; Per Hellman; Stan B. Sidhu; Gunnar Westin; Hendrik Lehnert

Background Aldosterone producing lesions are a common cause of hypertension, but genetic alterations for tumorigenesis have been unclear. Recently, either of two recurrent somatic missense mutations (G151R or L168R) was found in the potassium channel KCNJ5 gene in aldosterone producing adenomas. These mutations alter the channel selectivity filter and result in Na+ conductance and cell depolarization, stimulating aldosterone production and cell proliferation. Because a similar mutation occurs in a Mendelian form of primary aldosteronism, these mutations appear to be sufficient for cell proliferation and aldosterone production. The prevalence and spectrum of KCNJ5 mutations in different entities of adrenocortical lesions remain to be defined. Materials and Methods The coding region and flanking intronic segments of KCNJ5 were subjected to Sanger DNA sequencing in 351 aldosterone producing lesions, from patients with primary aldosteronism and 130 other adrenocortical lesions. The specimens had been collected from 10 different worldwide referral centers. Results G151R or L168R somatic mutations were identified in 47% of aldosterone producing adenomas, each with similar frequency. A previously unreported somatic mutation near the selectivity filter, E145Q, was observed twice. Somatic G151R or L168R mutations were also found in 40% of aldosterone producing adenomas associated with marked hyperplasia, but not in specimens with merely unilateral hyperplasia. Mutations were absent in 130 non-aldosterone secreting lesions. KCNJ5 mutations were overrepresented in aldosterone producing adenomas from female compared to male patients (63 vs. 24%). Males with KCNJ5 mutations were significantly younger than those without (45 vs. 54, respectively; p<0.005) and their APAs with KCNJ5 mutations were larger than those without (27.1 mm vs. 17.1 mm; p<0.005). Discussion Either of two somatic KCNJ5 mutations are highly prevalent and specific for aldosterone producing lesions. These findings provide new insight into the pathogenesis of primary aldosteronism.


Cancer | 2013

MicroRNA-222 and MicroRNA-146b are tissue and circulating biomarkers of recurrent papillary thyroid cancer

James C. Lee; Jing Ting Zhao; Roderick J. Clifton-Bligh; Anthony J. Gill; Justin S. Gundara; Julian Ip; Anthony R. Glover; Mark S. Sywak; Leigh Delbridge; Bruce G. Robinson; S. B. Sidhu

Papillary thyroid cancer (PTC) persistence or recurrence and the need for long‐term surveillance can cause significant inconvenience and morbidity in patients. Currently, recurrence risk stratification is accomplished by using clinicopathologic factors, and serum thyroglobulin is the only commercially available marker for persistent or recurrent disease. The objective of this study was to determine microRNA (miRNA) expression in PTC and determine whether 1 or more miRNAs could be measured in plasma as a biomarker for recurrence.


Scientific Reports | 2016

Activating mutations in CTNNB1 in aldosterone producing adenomas

Tobias Åkerström; Rajani Maharjan; Holger S. Willenberg; Kenko Cupisti; Julian Ip; Ana Moser; Peter Stålberg; Bruce G. Robinson; K. Alexander Iwen; Henning Dralle; Martin K. Walz; Hendrik Lehnert; Stan B. Sidhu; Celso E. Gomez-Sanchez; Per Hellman; Peyman Björklund

Primary aldosteronism (PA) is the most common cause of secondary hypertension with a prevalence of 5–10% in unreferred hypertensive patients. Aldosterone producing adenomas (APAs) constitute a large proportion of PA cases and represent a surgically correctable form of the disease. The WNT signaling pathway is activated in APAs. In other tumors, a frequent cause of aberrant WNT signaling is mutation in the CTNNB1 gene coding for β-catenin. Our objective was to screen for CTNNB1 mutations in a well-characterized cohort of 198 APAs. Somatic CTNNB1 mutations were detected in 5.1% of the tumors, occurring mutually exclusive from mutations in KCNJ5, ATP1A1, ATP2B3 and CACNA1D. All of the observed mutations altered serine/threonine residues in the GSK3β binding domain in exon 3. The mutations were associated with stabilized β-catenin and increased AXIN2 expression, suggesting activation of WNT signaling. By CYP11B2 mRNA expression, CYP11B2 protein expression, and direct measurement of aldosterone in tumor tissue, we confirmed the ability for aldosterone production. This report provides compelling evidence that aberrant WNT signaling caused by mutations in CTNNB1 occur in APAs. This also suggests that other mechanisms that constitutively activate the WNT pathway may be important in APA formation.


Oncotarget | 2015

microRNA-7 as a tumor suppressor and novel therapeutic for adrenocortical carcinoma

Anthony R. Glover; Jing Ting Zhao; Anthony J. Gill; Jocelyn Weiss; Nancy Mugridge; Edward S. Kim; Alex L Feeney; Julian Ip; Glen Reid; Stephen Clarke; Patsy S. Soon; Bruce G. Robinson; Himanshu Brahmbhatt; Jennifer MacDiarmid; Stan B. Sidhu

Adrenocortical carcinoma (ACC) has a poor prognosis with significant unmet clinical need due to late diagnosis, high rates of recurrence/metastasis and poor response to conventional treatment. Replacing tumor suppressor microRNAs (miRNAs) offer a novel therapy, however systemic delivery remains challenging. A number of miRNAs have been described to be under-expressed in ACC however it is not known if they form a part of ACC pathogenesis. Here we report that microRNA-7–5p (miR-7) reduces cell proliferation in vitro and induces G1 cell cycle arrest. Systemic miR-7 administration in a targeted, clinically safe delivery vesicle (EGFREDVTM nanocells) reduces ACC xenograft growth originating from both ACC cell lines and primary ACC cells. Mechanistically, miR-7 targets Raf-1 proto-oncogene serine/threonine kinase (RAF1) and mechanistic target of rapamycin (MTOR). Additionally, miR-7 therapy in vivo leads to inhibition of cyclin dependent kinase 1 (CDK1). In patient ACC samples, CDK1 is overexpressed and miR-7 expression inversely related. In summary, miR-7 inhibits multiple oncogenic pathways and reduces ACC growth when systemically delivered using EDVTM nanoparticles. This data is the first study in ACC investigating the possibility of miRNAs replacement as a novel therapy.


Endocrine-related Cancer | 2015

Novel somatic mutations and distinct molecular signature in aldosterone-producing adenomas

Tobias Åkerström; Holger S. Willenberg; Kenko Cupisti; Julian Ip; Samuel Backman; Ana Moser; Rajani Maharjan; Bruce G. Robinson; K. Alexander Iwen; Henning Dralle; Cristina Volpe; Johan Botling; Peter Stålberg; Gunnar Westin; Martin K. Walz; Hendrik Lehnert; Stan B. Sidhu; Jan Zedenius; Peyman Björklund; Per Hellman

Aldosterone-producing adenomas (APAs) are found in 1.5-3.0% of hypertensive patients in primary care and can be cured by surgery. Elucidation of genetic events may improve our understanding of these tumors and ultimately improve patient care. Approximately 40% of APAs harbor a missense mutation in the KCNJ5 gene. More recently, somatic mutations in CACNA1D, ATP1A1 and ATP2B3, also important for membrane potential/intracellular Ca(2) (+) regulation, were observed in APAs. In this study, we analyzed 165 APAs for mutations in selected regions of these genes. We then correlated mutational findings with clinical and molecular phenotype using transcriptome analysis, immunohistochemistry and semiquantitative PCR. Somatic mutations in CACNA1D in 3.0% (one novel mutation), ATP1A1 in 6.1% (six novel mutations) and ATP2B3 in 3.0% (two novel mutations) were detected. All observed mutations were located in previously described hotspot regions. Patients with tumors harboring mutations in CACNA1D, ATP1A1 and ATP2B3 were operated at an older age, were more often male and had tumors that were smaller than those in patients with KCNJ5 mutated tumors. Microarray transcriptome analysis segregated KCNJ5 mutated tumors from ATP1A1/ATP2B3 mutated tumors and those without mutation. We observed significant transcription upregulation of CYP11B2, as well as the previously described glomerulosa-specific gene NPNT, in ATP1A1/ATP2B3 mutated tumors compared to KCNJ5 mutated tumors. In summary, we describe novel somatic mutations in proteins regulating the membrane potential/intracellular Ca(2) (+) levels, and also a distinct mRNA and clinical signature, dependent on genetic alteration.


Endocrine-related Cancer | 2015

Long noncoding RNA profiles of adrenocortical cancer can be used to predict recurrence

Anthony R. Glover; Jing Ting Zhao; Julian Ip; James C. Lee; Bruce G. Robinson; Anthony J. Gill; Patsy S. Soon; Stan B. Sidhu

Adrenocortical carcinoma (ACC) is an aggressive malignancy with high rates of recurrence following surgical resection. Long noncoding RNAs (lncRNAs) play an important role in cancer development. Pathogenesis of adrenal tumours have been characterised by mRNA, microRNA and methylation expression signatures, but it is unknown if this extends to lncRNAs. This study describes lncRNA expression signatures in ACC, adrenal cortical adenoma (ACA) and normal adrenal cortex (NAC) and presents lncRNAs associated with ACC recurrence to identify novel prognostic and therapeutic targets. RNA was extracted from freshly frozen tissue with confirmation of diagnosis by histopathology. Focused lncRNA and mRNA transcriptome analysis was performed using the ArrayStar Human LncRNA V3.0 microarray. Differentially expressed lncRNAs were validated using quantitative reverse transcriptase-PCR and correlated with clinical outcomes. Microarray of 21 samples (ten ACCs, five ACAs and six NACs) showed distinct patterns of lncRNA expression between each group. A total of 956 lncRNAs were differentially expressed between ACC and NAC, including known carcinogenesis-related lncRNAs such as H19, GAS5, MALAT1 and PRINS (P≤0.05); 85 lncRNAs were differentially expressed between ACC and ACA (P≤0.05). Hierarchical clustering and heat mapping showed ACC samples correctly grouped compared with NAC and ACA. Sixty-six differentially expressed lncRNAs were found to be associated with ACC recurrence (P≤0.05), one of which, PRINS, was validated in a group of 20 ACCs and also found to be associated with metastatic disease on presentation. The pathogenesis of adrenal tumours extends to lncRNA dysregulation and low expression of the lncRNA PRINS is associated with ACC recurrence.


OncoTargets and Therapy | 2013

Current management options for recurrent adrenocortical carcinoma.

Anthony R. Glover; Julian Ip; Jing Ting Zhao; Patsy S. Soon; Bruce G. Robinson; Stan B. Sidhu

Adrenal cortical carcinoma (ACC) is a rare cancer that poses a number of management challenges due to the limited number of effective systemic treatments. Complete surgical resection offers the best chance of long-term survival. However, despite complete resection, ACC is associated with high recurrence rates. This review will discuss the management of recurrent ACC in adults following complete surgical resection. Management should take place in a specialist center and treatment decisions must consider the individual tumor biology of each case of recurrence. Given the fact that ACC commonly recurs, management to prevent recurrence should be considered from initial diagnosis with the use of adjuvant mitotane. Close follow up with clinical examination and imaging is important for early detection of recurrent disease. Locoregional recurrence may be isolated, and repeat surgical resection should be considered along with mitotane. The use of radiotherapy in ACC remains controversial. Systemic recurrence most often involves liver, pulmonary, and bone metastasis and is usually managed with mitotane, with or without combination chemotherapy. There is a limited role for surgical resection in systemic recurrence in selected patients. In all patients with recurrent disease, control of excessive hormone production is an important part of management. Despite intensive management of recurrent ACC, treatment failure is common and the use of clinical trials and novel treatment is an important part of management.


Oncologist | 2015

Immunohistochemical validation of overexpressed genes identified by global expression microarrays in adrenocortical carcinoma reveals potential predictive and prognostic biomarkers.

Julian Ip; Tony Pang; Anthony R. Glover; Patsy S. Soon; Jing Ting Zhao; Stephen Clarke; Bruce G. Robinson; Anthony J. Gill; Stan B. Sidhu

BACKGROUND Adrenocortical carcinoma (ACC) is a rare malignancy with a poor prognosis. The aim of this study was to identify novel protein signatures that would predict clinical outcomes in a large cohort of patients with ACC based on data from previous gene expression microarray studies. MATERIALS AND METHODS A tissue microarray was generated from the paraffin tissue blocks of 61 patients with clinical outcomes data. Selected protein biomarkers based on previous gene expression microarray profiling studies were selected, and immunohistochemistry staining was performed. Staining patterns were correlated with clinical outcomes, and a multivariate analysis was undertaken to identify potential biomarkers of prognosis. RESULTS Median overall survival was 45 months, with a 5-year overall survival rate of 44%. Median disease-free survival was 58 months, with a 5-year disease-free survival rate of 44%. The proliferation marker Ki-67 and DNA topoisomerase TOP2A were associated with significantly poorer overall and disease-free survival. The results also showed strong correlation between the transcriptional repressor EZH2 and TOP2A expression, suggesting a novel role for EZH2 as an additional marker of prognosis. In contrast, increased expression of the BARD1 protein, with its ubiquitin ligase function, was associated with significantly improved overall and disease-free survival, which has yet to be documented for ACC. CONCLUSION We present novel biomarkers that assist in determining prognosis for patients with ACC. Ki-67, TOP2A, and EZH2 were all significantly associated with poorer outcomes, whereas BARD1 was associated with improved overall survival. It is hoped that these biomarkers may help tailor additional therapy and be potential targets for directed therapy.


Anz Journal of Surgery | 2015

Mutations in KCNJ5 determines presentation and likelihood of cure in primary hyperaldosteronism

Julian Ip; Tony Pang; Cindy K. Pon; Jing Ting Zhao; Mark S. Sywak; Anthony J. Gill; Patsy S. Soon; Stan B. Sidhu

Primary hyperaldosteronism (PA) is a common cause of secondary hypertension. Two recurrent mutations (G151R and L168R) in the potassium channel gene KCNJ5 have been identified that affect the Kir3.4 potassium channel found in the cells of the zona glomerulosa of the adrenal gland. The aim of this study was to determine the prevalence of KCNJ5 mutations in an Australian cohort of patients and to correlate these findings with clinical outcome data, in order to describe the clinical impact on patients who harbour this mutation.


Anz Journal of Surgery | 2012

Unusually complicated chest infection: colon containing intercostal hernia

Justin S. Gundara; Julian Ip; James C. Lee

Acute presentation of an intercostal hernia harbouring abdominal viscera is rare. While usually of post-traumatic aetiology, here we describe a spontaneous case requiring emergent repair. An 88-year-old, overweight woman presented with a painful left flank. The swelling had developed over a 3-day period on a background of coughing due to a recent lower respiratory tract infection. Upon examination, the patient was found to have a large, ill-defined swelling extending from the left, lower posterolateral chest to the iliac crest and extending anteriorly onto the abdominal wall. The swelling was erythematous, warm to palpation and generally tender. Computed tomography definition of what was thought clinically to represent a subcutaneous haematoma revealed a large intercostal, chest wall hernia containing descending colon (Figs 1,2). The hernia neck resided between the 9th and 10th ribs and was 3.5 cm wide. Colon within the hernia sac appeared viable, and proximal bowel loops in the peritoneal cavity were non-specifically dilated. An associated mild left pleural effusion and subcutaneous haematoma were present. At operation, a midline laparotomy was performed to reduce the hernia contents and drain the associated haematoma. Bowel was found to be viable and resection was not necessary. There was no diaphragmatic defect or breach of the pleural space. The intercostal hernia defect was covered by a sublay composite mesh and secured by suture and tack fixation. The abdomen was closed in layers and the patient was transferred to the intensive care unit. Her post-operative course was significant for a left-sided pleural effusion requiring percutaneous drainage. The patient otherwise made a steady recovery and was discharged to a rehabilitation facility on day 9. Follow-up at 3 months demonstrated a satisfactory recovery, with resumption of independent functional activities and an absence of ongoing pulmonary and/or abdominal issues. Abdominal intercostal herniation (AIH) is a rare diagnosis that has previously been reported in adult populations. Most AIH occurs in the left hemi-thorax below the level of the 8th rib. In an effort to explain the phenomenon, Biswas and Keddington relied on anatomy to forward an explanation. They cited the lack of an external intercostal muscle layer anteriorly (between the costochondral junction and sternocostal joint) and an internal intercostal muscle layer posteriorly (between the angle of the rib and costovertebral joint) as being fundamental to the development of natural areas of thoracic wall soft tissue weakness. Any subsequent weakness of the intercostal layer (e.g. trauma) then further compromises this tissue plane and further diaphragmatic weakness or trauma sets the scene for potential visceral dislocation through the double-breasted defect. Weakness may ensue following direct trauma (both penetrating and non-penetrating) or repetitive stress, as in the present case with the patient suffering from a chronic cough. Penetrating trauma with what effectively constitutes an incisional hernia is the most common

Collaboration


Dive into the Julian Ip's collaboration.

Top Co-Authors

Avatar

Bruce G. Robinson

Kolling Institute of Medical Research

View shared research outputs
Top Co-Authors

Avatar

Stan B. Sidhu

Royal North Shore Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jing Ting Zhao

Kolling Institute of Medical Research

View shared research outputs
Top Co-Authors

Avatar

Patsy S. Soon

University of New South Wales

View shared research outputs
Top Co-Authors

Avatar

Anthony J. Gill

Kolling Institute of Medical Research

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Justin S. Gundara

Royal North Shore Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge